SeaStar Medical Secures FDA Breakthrough Designation for Sepsis Treatment

  • FDA granted SeaStar Medical Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult sepsis patients.
  • This is the seventh Breakthrough Device Designation for SeaStar Medical's SCD therapy across various indications.
  • Sepsis affects 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths.
  • SeaStar Medical's NEUTRALIZE-AKI pivotal clinical trial includes a subset analysis for sepsis patients, with data expected soon.

SeaStar Medical's latest Breakthrough Device Designation underscores the critical need for innovative therapies in sepsis, a condition with high mortality and limited treatment options. The designation could expedite the development and review process, potentially providing a significant advantage in the competitive landscape of critical care therapies. The company's focus on immunomodulation with its SCD platform positions it uniquely to address multiple life-threatening conditions driven by hyperinflammation.

Regulatory Pathway
The pace at which SeaStar Medical can submit and gain FDA approval for this new indication.
Clinical Data
Whether the upcoming data from the NEUTRALIZE-AKI trial will support the efficacy of SCD therapy in sepsis patients.
Market Potential
How the Breakthrough Device Designation could accelerate commercialization and reimbursement for SCD therapy.